Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $33.1 million.

  • Kiniksa Pharmaceuticals International's Free Cash Flow rose 156436.48% to $33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.8 million, marking a year-over-year increase of 82700.46%. This contributed to the annual value of $25.4 million for FY2024, which is 9293.9% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Free Cash Flow stood at $33.1 million, which was up 156436.48% from $27.9 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Free Cash Flow peaked at $62.0 million during Q3 2022, and registered a low of -$40.2 million during Q1 2021.
  • Its 5-year average for Free Cash Flow is $44368.4, with a median of -$2.3 million in 2024.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Free Cash Flow crashed by 11331.17% in 2024 and then surged by 156436.48% in 2025.
  • Kiniksa Pharmaceuticals International's Free Cash Flow (Quarter) stood at -$19.1 million in 2021, then soared by 39.67% to -$11.5 million in 2022, then skyrocketed by 136.98% to $4.3 million in 2023, then soared by 337.9% to $18.7 million in 2024, then surged by 76.96% to $33.1 million in 2025.
  • Its Free Cash Flow stands at $33.1 million for Q3 2025, versus $27.9 million for Q2 2025 and $22.2 million for Q1 2025.